A Phase 1, Multicenter, Open-Label Study of CHS-1000 as a Single Agent and in Combination With Toripalimab-tpzi in Participants With Advanced or Metastatic Solid Tumors
Latest Information Update: 27 Sep 2024
At a glance
- Drugs CHS 1000 (Primary) ; Toripalimab
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Coherus Biosciences
Most Recent Events
- 19 Sep 2024 Planned End Date changed from 30 Jan 2028 to 30 May 2028.
- 19 Sep 2024 Planned primary completion date changed from 30 Jan 2028 to 30 May 2028.
- 19 Sep 2024 Planned initiation date changed from 1 Oct 2024 to 15 Feb 2025.